CL2004000208A1 - COMPOSICION FARMACEUTICA QUE COMPRENDE: i) UNA BASE LIQUIDA CON 50-300mg/100ml DE SUCRALOSA PARA DISIMULAR SABOR AMARGO DE UN ACTIVO Y II) AL MENOS UN ACTIVO SELECCIONADO ENTRE ANTIHISTAMINAS, DESCONGESTIONANTES, ANTITUSIVOS, EXPECTORANTES, ANTIBIOTI - Google Patents

COMPOSICION FARMACEUTICA QUE COMPRENDE: i) UNA BASE LIQUIDA CON 50-300mg/100ml DE SUCRALOSA PARA DISIMULAR SABOR AMARGO DE UN ACTIVO Y II) AL MENOS UN ACTIVO SELECCIONADO ENTRE ANTIHISTAMINAS, DESCONGESTIONANTES, ANTITUSIVOS, EXPECTORANTES, ANTIBIOTI

Info

Publication number
CL2004000208A1
CL2004000208A1 CL200400208A CL2004000208A CL2004000208A1 CL 2004000208 A1 CL2004000208 A1 CL 2004000208A1 CL 200400208 A CL200400208 A CL 200400208A CL 2004000208 A CL2004000208 A CL 2004000208A CL 2004000208 A1 CL2004000208 A1 CL 2004000208A1
Authority
CL
Chile
Prior art keywords
asset
descongestionants
antibusts
antibiovants
ambar
Prior art date
Application number
CL200400208A
Other languages
English (en)
Spanish (es)
Inventor
David Jaeger
Jay Dickerson
Anabelle Mogavero
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23195896&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2004000208(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of CL2004000208A1 publication Critical patent/CL2004000208A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CL200400208A 2001-07-31 2004-02-06 COMPOSICION FARMACEUTICA QUE COMPRENDE: i) UNA BASE LIQUIDA CON 50-300mg/100ml DE SUCRALOSA PARA DISIMULAR SABOR AMARGO DE UN ACTIVO Y II) AL MENOS UN ACTIVO SELECCIONADO ENTRE ANTIHISTAMINAS, DESCONGESTIONANTES, ANTITUSIVOS, EXPECTORANTES, ANTIBIOTI CL2004000208A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30891201P 2001-07-31 2001-07-31
PCT/US2002/024298 WO2003011306A1 (en) 2001-07-31 2002-07-31 Sucralose formulations to mask unpleasant tastes

Publications (1)

Publication Number Publication Date
CL2004000208A1 true CL2004000208A1 (es) 2005-03-18

Family

ID=23195896

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200400208A CL2004000208A1 (es) 2001-07-31 2004-02-06 COMPOSICION FARMACEUTICA QUE COMPRENDE: i) UNA BASE LIQUIDA CON 50-300mg/100ml DE SUCRALOSA PARA DISIMULAR SABOR AMARGO DE UN ACTIVO Y II) AL MENOS UN ACTIVO SELECCIONADO ENTRE ANTIHISTAMINAS, DESCONGESTIONANTES, ANTITUSIVOS, EXPECTORANTES, ANTIBIOTI

Country Status (13)

Country Link
US (2) US20060121066A1 (enExample)
EP (1) EP1411955A4 (enExample)
JP (2) JP2004538309A (enExample)
AU (1) AU2002324579B2 (enExample)
BR (1) BR0211794A (enExample)
CA (1) CA2455939C (enExample)
CL (1) CL2004000208A1 (enExample)
CO (1) CO5560580A2 (enExample)
CR (1) CR7264A (enExample)
EC (1) ECSP044995A (enExample)
MX (1) MXPA04001026A (enExample)
NZ (1) NZ530889A (enExample)
WO (1) WO2003011306A1 (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030211136A1 (en) * 1998-09-25 2003-11-13 Neema Kulkarni Fast dissolving orally consumable films containing a sweetener
WO2005072717A1 (ja) * 2004-01-29 2005-08-11 Dainippon Sumitomo Pharma Co., Ltd. ビグアナイド系薬物の内服製剤
US20070020330A1 (en) * 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
EP2522365B1 (en) 2004-11-24 2016-10-26 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
US8435588B2 (en) * 2005-11-23 2013-05-07 The Coca-Cola Company High-potency sweetener composition with an anti-inflammatory agent and compositions sweetened therewith
US9101160B2 (en) 2005-11-23 2015-08-11 The Coca-Cola Company Condiments with high-potency sweetener
US8940796B2 (en) 2006-02-21 2015-01-27 Wyeth Llc Phenylephrine liquid formulations
US10022339B2 (en) 2006-04-21 2018-07-17 The Procter & Gamble Company Compositions and methods useful for treatment of respiratory illness
US20070249727A1 (en) * 2006-04-21 2007-10-25 The Proctor & Gamble Company Compositions and kits useful for treatment of respiratory illness
US20080014274A1 (en) 2006-07-14 2008-01-17 Wyeth Enhanced stability phenylephrine liquid compositions
US9005652B2 (en) 2006-07-25 2015-04-14 Wyeth Chewable tablet containing phenylephrine
US8017168B2 (en) 2006-11-02 2011-09-13 The Coca-Cola Company High-potency sweetener composition with rubisco protein, rubiscolin, rubiscolin derivatives, ace inhibitory peptides, and combinations thereof, and compositions sweetened therewith
US8323695B2 (en) * 2007-08-13 2012-12-04 Mcneil-Ppc, Inc. Method for stabilizing phenylephrine
JP2013053136A (ja) * 2011-08-09 2013-03-21 Taisho Pharmaceutical Co Ltd 内服液剤
US20150025103A1 (en) 2011-12-09 2015-01-22 Wochkardt Limited Oral liquid concentrate comprising brompheniramine, pseudoephedrine and dextromethorphan
US20150056288A1 (en) 2011-12-14 2015-02-26 Wockhardt Limited Modified release liquid pharmaceutical composition comprising bromopheniramine, pseudoephedrine and dextromethorphan
US8568747B1 (en) 2012-10-05 2013-10-29 Silvergate Pharmaceuticals, Inc. Enalapril compositions
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
HRP20221344T1 (hr) * 2013-11-13 2022-12-23 National Defense Education And Research Foundation Novi pripravak acetaminofenskog spoja bez nuspojave po jetru
JP6565334B2 (ja) * 2014-06-18 2019-08-28 大正製薬株式会社 固形製剤
CN105640956B (zh) * 2014-11-14 2018-09-14 澳美制药厂有限公司 不含防腐剂的复方磷酸可待因组合口服液及其制备方法
GR1009069B (el) * 2015-01-05 2017-07-07 Λαμδα Φαρμακευτικα Εργαστηρια Εφαρμοσμενης Ερευνας & Αναπτυξης Α.Ε. Ποσιμα διαλυματα υψηλης συγκεντρωσης που περιεχουν υδροχλωρικη ρανιτιδινη
US20160317497A1 (en) * 2015-05-01 2016-11-03 Trinity Ent And Facial Aesthetics Flavored analgesic and decongestant spray
JP6794758B2 (ja) * 2015-10-21 2020-12-02 大正製薬株式会社 経口液体医薬組成物
EP3181150A1 (de) * 2015-12-19 2017-06-21 Analyticon Discovery GmbH Pharmazeutische zubereitungen
HUE053114T2 (hu) 2015-12-22 2021-06-28 Zogenix International Ltd Fenfluramin kompozíciók és eljárások azok elõállítására
WO2017112701A1 (en) 2015-12-22 2017-06-29 Zogenix International Limited Metabolism resistant fenfluramine analogs and methods of using the same
US9669008B1 (en) 2016-03-18 2017-06-06 Silvergate Pharmaceuticals, Inc. Enalapril formulations
GB2551971B (en) * 2016-06-29 2020-09-16 Syri Ltd Taste masked liquid pharmaceutical composition of mebeverine or pharmaceutically acceptable salts thereof
WO2018037306A1 (en) 2016-08-24 2018-03-01 Zogenix International Limited Formulation for inhibiting formation of 5-ht 2b agonists and methods of using same
US20210069127A1 (en) * 2017-03-27 2021-03-11 DXM Pharmaceuticals, Inc. Multi-Dose Concentrated Liquid Diphenhydramine HCl Compositions and Packaged Multi-Dose Liquid Diphenhydramine HCl Formulations
US11234897B2 (en) 2017-03-27 2022-02-01 DXM Pharmaceutical, Inc. Packaged multi-dose liquid dextromethorphan hydrobromide formulation
US10682317B2 (en) * 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
CA3097335A1 (en) 2018-05-11 2019-11-14 Zogenix International Limited Compositions and methods for treating seizure-induced sudden death
JP6858729B2 (ja) * 2018-05-25 2021-04-14 ▲財▼▲団▼法人国防教育研究基金会Ｎａｔｉｏｎａｌ Ｄｅｆｅｎｓｅ Ｅｄｕｃａｔｉｏｎ Ａｎｄ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ 肝臓に対する副作用がない、新しいアセトアミノフェン複合組成
EP3806835A1 (en) 2018-06-14 2021-04-21 Zogenix International Limited Compositions and methods for treating respiratory depression with fenfluramine
SG11202104378SA (en) 2018-11-19 2021-05-28 Zogenix International Ltd Methods of treating rett syndrome using fenfluramine
US12053447B2 (en) 2019-06-25 2024-08-06 NuBioPharma, LLC Oral solution and powder to liquid compositions of balsalazide
CN110279695B (zh) * 2019-08-07 2022-04-08 北京博智绿洲医药科技有限公司 一种治疗流涕、鼻塞等感冒症状的药物组合物及其制备方法和用途
CN110302149A (zh) * 2019-08-07 2019-10-08 北京博达绿洲医药科技研究有限公司 一种适合4-11岁儿童服用抗感冒药物及其制备方法
CN110327339A (zh) * 2019-08-07 2019-10-15 北京博达绿洲医药科技研究有限公司 一种复方右美沙芬口服溶液及其制备方法和用途
CN112439072A (zh) * 2019-08-29 2021-03-05 鲁南制药集团股份有限公司 一种掩味组合物及其制备方法、用途
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
CN117122562A (zh) * 2022-05-21 2023-11-28 山东百诺医药股份有限公司 一种美芬那敏铵口服溶液

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4552899A (en) * 1984-04-09 1985-11-12 Analgesic Associates Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs
US4892877A (en) * 1987-10-27 1990-01-09 Richardson-Vicks Inc. Antitussive liquid compositions containing phenol
US5013716A (en) * 1988-10-28 1991-05-07 Warner-Lambert Company Unpleasant taste masking compositions and methods for preparing same
NZ234143A (en) * 1989-06-28 1991-10-25 Mcneil Ppc Inc Aqueous pharmaceutical suspension formulation for administering substantially insoluble pharmaceutical agents
NZ240818A (en) * 1990-12-14 1993-08-26 Mcneil Ppc Inc Liquid sucralose concentrate compositions containing preservative, buffer and liquid
US5164398A (en) * 1991-04-01 1992-11-17 Merck & Co., Inc. Ibuprofen-antitussive combinations
US5272137A (en) * 1992-02-14 1993-12-21 Mcneil-Pfc, Inc. Aqueous pharmaceutical suspension for pharmaceutical actives
US5422508A (en) * 1992-09-21 1995-06-06 Siliconix Incorporated BiCDMOS structure
NO941358L (no) * 1993-04-16 1994-10-17 Mcneil Ppc Inc Vandig farmasöytisk suspensjon og fremgangsmåte for fremstilling derav
JPH09508128A (ja) * 1994-01-24 1997-08-19 ザ、プロクター、エンド、ギャンブル、カンパニー 難溶性医薬活性剤の溶解方法
US5458879A (en) * 1994-03-03 1995-10-17 The Procter & Gamble Company Oral vehicle compositions
US5773647A (en) * 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5885594A (en) * 1997-03-27 1999-03-23 The Procter & Gamble Company Oral compositions having enhanced mouth-feel
JP2000135055A (ja) * 1998-10-29 2000-05-16 Sanei Gen Ffi Inc 乳感の向上した乳含有製品
MXPA02003312A (es) * 1999-09-29 2002-10-04 Procter & Gamble Composiciones que tienen estabilidad mejorada.
JP2001106639A (ja) * 1999-10-04 2001-04-17 Taisho Pharmaceut Co Ltd 経口用組成物
DE19961897A1 (de) * 1999-12-20 2001-06-28 Basf Ag Verwendung eines Filmüberzuges als geschmacksmaskierendes Coating von pharmazeutischen Darreichungsformen

Also Published As

Publication number Publication date
CR7264A (es) 2004-05-17
CA2455939C (en) 2011-03-22
CA2455939A1 (en) 2003-02-13
BR0211794A (pt) 2004-11-03
WO2003011306A1 (en) 2003-02-13
CO5560580A2 (es) 2005-09-30
US20110136851A1 (en) 2011-06-09
JP2010090142A (ja) 2010-04-22
ECSP044995A (es) 2004-04-28
AU2002324579B2 (en) 2007-11-15
EP1411955A4 (en) 2006-07-05
JP2004538309A (ja) 2004-12-24
EP1411955A1 (en) 2004-04-28
MXPA04001026A (es) 2005-06-20
NZ530889A (en) 2005-03-24
US20060121066A1 (en) 2006-06-08

Similar Documents

Publication Publication Date Title
CL2004000208A1 (es) COMPOSICION FARMACEUTICA QUE COMPRENDE: i) UNA BASE LIQUIDA CON 50-300mg/100ml DE SUCRALOSA PARA DISIMULAR SABOR AMARGO DE UN ACTIVO Y II) AL MENOS UN ACTIVO SELECCIONADO ENTRE ANTIHISTAMINAS, DESCONGESTIONANTES, ANTITUSIVOS, EXPECTORANTES, ANTIBIOTI
EE05475B1 (et) Superantigeeni sisaldav konjugaat, konjugaadi kasutamine ja konjugaati sisaldav farmatseutiline kompositsioon
NO20035298D0 (no) CDK-inhiberende pyrimider, deres fremstilling og deres anvendelse som legemidler
NO20025357D0 (no) Antranylamider og deres anvendelse som legemidler
MXPA03002568A (es) Derivados de sulfonamida farmaceuticamente activos que incluyen fracciones lipofilicas e ionizables como inhibidores de proteinas junquinasas.
NO20025450L (no) Ny farmasöytisk sammensetning
ITTO20010005A1 (it) Formulazione farmaceutica.
EE200300228A (et) Tiotroopium- ja salmeteroolsooladel põhinevad ravimkompositsioonid
NO20026037L (no) Sötvareprodukt som inneholder aktive bestanddeler
DK1792927T3 (da) Ny blokcopolymer, micelletilberedning og anticancermiddel indeholdende samme som aktiv ingrediens
DK1445252T3 (da) Sulfonamid-derivater, deres fremstilling og anvendelse som medikamenter
NL1015859A1 (nl) Farmaceutische preparaten.
NO20024534L (no) FremgangsmÕte for Õ sende annonseringsmeldinger
BRPI0013439B1 (pt) composiÇço compreendendo tramadol e um fÁrmaco anticonvulsivante.
EP1513825A4 (en) ANTITU-CULINARY MEDICAMENT: COMPOSITIONS AND METHODS
NO20005146D0 (no) Tienylazolylalkoksyetanaminer, deres fremstilling og deres anvendelse som medikamenter
DK1268419T3 (da) Farmaceutisk aktive pyrrolidinderivater som BAX-inhibitorer
DE60233891D1 (de) Selektives targeting von apoptotischen zellen
MXPA03000471A (es) Transportador de grabacion para almacenar un trabajo digital.
DK1387838T3 (da) Cyanoanthranylamid-derivater og deres anvendelse som lægemidler
DK1643976T3 (da) Farmaceutisk formulering omfattende levothyroxinnatrium
NO20032614L (no) Farmasöytisk sammensetning som har forbedret absorberbarhet
DK1387842T3 (da) Bredspektrede 2-amino-benzoxazolsulfonamid-HIV-protease-inhibitorer
DK1753725T3 (da) Tetra-hydro-iso-quinolinsulfonamidderivater, fremstilling og terapeutisk anvendelse heraf.
NO20030998L (no) Arylpiperazinderivater og deres anvendelse som psykotropiske midler